oxymorphone trials begin, page-12

Looks like this trial will be done first to allow it to catch up with tje PK results of the oxypatch. This will give 2 products with pks for mutidosing around the time the fda make the decision re abusable generics being banned(perhaps). And in early deal before either actually starts phase2/3 later in q3/4 and bang. We have a sold pain portfolio.

We see how the duckies are lining up. If there are several suitors and with multidose results in the bag with the known drugs involved no one will wait for phase 3 to do a deal. It will be a race and highest bidder wins. Perhaps sweetened with options on future opiod patches.

What was that King deal a few years back? $3.5 bollion cash for their portfolio. This could crack a billion in total deal value to POH.

And you sold at 14c.....